Who can be vaccinated with LAIV?
LAIV can be given to healthy, nonpregnant people ages 5-49 years. This includes health care workers and family members who will be in close contact with people at high risk for severe complications to influenza infection. When TIV is in short supply, use of LAIV is encouraged for people who are eligible, because this may increase availability of TIV for people in high-risk groups. Advantages of LAIV include its potential to induce a broad mucosal and systemic immune response, ease of administration, and the acceptance of an intranasal, rather than intramuscular, route of injection.
